Download PDF
Fortschr Neurol Psychiatr 2019; 87(08): 445-461
DOI: 10.1055/a-0952-8075
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Neues zu Diagnostik und Therapie des idiopathischen Parkinson-Syndroms

Update on diagnostics and therapy of idiopathic Parkinson’s disease
Josefine Waldthaler
,
Lars Timmermann
Further Information

Publication History

Publication Date:
20 August 2019 (online)

   Permissions and Reprints

In Deutschland leben mindestens 300000 Menschen mit einem idiopathischen Parkinson-Syndrom. Aufgrund des demografischen Wandels ist mit einer stetig steigenden Zahl Betroffener zu rechnen. In diesem Beitrag werden die evidenzbasierte Diagnostik und Therapie des idiopathischen Parkinson-Syndroms dargestellt. Insbesondere soll ein Überblick über die neuen Erkenntnisse und Entwicklungen der letzten Jahre gegeben werden.

At least 300,000 people with idiopathic Parkinson’s disease are living in Germany. Due to the demographic change the number of affected patients is expected to increase continuously. This article presents the evidence-based diagnostics and therapy of idiopathic Parkinson’s disease. It provides an overview especially on new findings and developments in recent years.

Schlüsselwörter

idiopathisches Parkinson-Syndrom - Bewegungsstörung - neurodegenerative Erkrankung - L-Dopatiefe Hirnstimulation

Key words

idiopathic Parkinson’s disease - movement disorder - neurodegeneration - L-Dopadeep brain stimulation
 

  • Literatur

  • 1 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinsonʼs disease. Mov Disord 2015; 30: 1591-1601
    CrossrefPubMedGoogle Scholar
  • 2 Deutsche Gesellschaft für Neurologie – DGN. S3-Leitlinie Idiopathisches Parkinson-Syndrom. In: Leitlinien für Diagnostik und Therapie in der Neurologie. DGN; 2016 . Im Internet: https://www.awmf.org/leitlinien/detail/ll/030-010.html; Stand: 28.12.2018
    PubMed
  • 3 Danel SE, Lees AJ. Parkinsonʼs Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993; 39: 165-172
    PubMedGoogle Scholar
  • 4 Pavese N, Tai YF. Nigrosome imaging and neuromelanin sensitive mri in diagnostic evaluation of Parkinsonism. Mov Disord Clin Pract 2018; 5: 131-140
    CrossrefPubMedGoogle Scholar
  • 5 Tripathi M, Dhawan V, Peng S. et al. Differential diagnosis of parkinsonian syndromes using F‑18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013; 55: 483-492
    CrossrefPubMedGoogle Scholar
  • 6 Domingo A, Klein C. Genetics of Parkinson Disease. Handb Clin Neurol 2018; 147: 211-227 . doi:10.1016/B978-0-444-63233-3.00014-2
    PubMedGoogle Scholar
  • 7 Berg D, Postuma RB, Adler CH. et al. MDS research criteria for prodromal Parkinsonʼs disease. Mov Disord 2015; 30: 1600-1611
    CrossrefPubMedGoogle Scholar
  • 8 Fereshtehnejad SM, Romenets SR, Anang JBM. et al. New clinical subtypes of Parkinson disease and their longitudinal progression. JAMA Neurol 2015; 72: 863-873
    CrossrefPubMedGoogle Scholar
  • 9 Seppi K, Weintraub D, Coelho M. et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinsonʼs disease. Mov Disord 2011; 26 (Suppl 3): S42-S80
    CrossrefPubMedGoogle Scholar
  • 10 Fox SH, Katzenschlager R, Lim SY. et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson ʼs disease. Mov Disord 2018; 33: 1248-1266
    CrossrefPubMedGoogle Scholar
  • 11 Weintraub D, David AS, Evans AH. et al. Clinical spectrum of impulse control disorders in Parkinsonʼs disease. Mov Disord 2015; 30: 121-127
    CrossrefPubMedGoogle Scholar
  • 12 Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinsonʼs disease? J Neurol 2005; 252 (Suppl 4): IV37-IV42
    PubMed
  • 13 Ferreira JJ, Lees A, Rocha JF. et al. Opicapone as an adjunct to levodopa in patients with Parkinsonʼs disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol 2016; 15: 154-165
    CrossrefPubMedGoogle Scholar
  • 14 Schapira AHV, Fox SH, Hauser RA. et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74: 216-224
    CrossrefPubMedGoogle Scholar
  • 15 [No authors listed]. Deep brain stimulation for Parkinsonʼs disease with early motor complications. JAMA 2014; 311: 1686-1687
    CrossrefPubMedGoogle Scholar
  • 16 Antonini A, Moro E, Godeiro C. et al. Medical and surgical management of advanced Parkinsonʼs disease. Mov Disord 2018; 33: 900-908
    CrossrefPubMedGoogle Scholar
  • 17 Vasconcellos LFR, Pereira JS. Parkinsonʼs disease dementia: Diagnostic criteria and risk factor review. J Clin Exp Neuropsychol 2015; 37: 988-993
    CrossrefPubMedGoogle Scholar
  • 18 Mathis M V, Muoio BM, Andreason P. et al. The US Food and Drug Administrationʼs perspective on the new antipsychotic pimavanserin. J Clin Psychiat 2017; 78: 668-673
    CrossrefPubMedGoogle Scholar
  • 19 Henderson EJ, Lord SR, Brodie MA. et al. Rivastigmine for gait stability in patients with Parkinsonʼs disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 249-258
    CrossrefPubMedGoogle Scholar
  • 20 Tomlinson CL, Patel S, Meek C. et al. Physiotherapy versus placebo or no intervention in Parkinsonʼs disease. Cochrane Database Syst Rev 2013; (09): CD002817 . doi:10.1002/14651858.CD002817.pub4
    PubMedGoogle Scholar
  • 21 Da Silva FC, Iop RDR, De Oliveira LC. et al. Effects of physical exercise programs on cognitive function in Parkinsonʼs disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One 2018; 13: e0193113 . doi:10.1371/journal.pone.0193113
    CrossrefPubMedGoogle Scholar